Online citations, reference lists, and bibliographies.
← Back to Search

Outcomes Of The Multimodal Treatment Of Malignant Pleural Mesiothelioma: The Role Of Surgery

Bub-Se Na, J. Kim, Kwanyong Hyun, I. Park, C. Kang, Y. Kim
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Background The treatment of malignant pleural mesothelioma (MPM) is challenging, and multimodal treatment including surgery is recommended; however, the role of surgery is debated. The treatment outcomes of MPM in Korea have not been reported. We analyzed the outcomes of MPM in the context of multimodal treatment, including surgery. Methods The records of 29 patients with pathologically proven MPM from April 1998 to July 2015 were retrospectively reviewed. The treatment outcomes of the surgery and non-surgery groups were compared. Results The overall median survival time was 10.6 months, and the overall 3-year survival rate was 25%. No postoperative 30-day or in-hospital mortality occurred in the surgery group. Postoperative complications included tachyarrhythmia (n=4), pulmonary thromboembolism (n=1), pneumonia (n=1), chylothorax (n=1), and wound complications (n=3). The treatment outcomes between the surgery and non-surgery groups were not significantly different (3-year survival rate: 31.3% vs. 16.7%, respectively; p=0.47). In a subgroup analysis, there was no significant difference in the treatment outcomes between the extrapleural pneumonectomy group and the non-surgery group (3-year survival rate: 45.5% vs. 16.7%, respectively; p=0.23). Conclusion Multimodal treatment incorporating surgery did not show better outcomes than non-surgical treatment. A nationwide multicenter data registry and prospective randomized controlled studies are necessary to optimize the treatment of MPM.
This paper references
10.1016/j.lungcan.2013.11.026
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
10.21037/atm.2017.04.05
Randomized controlled trials in malignant pleural mesothelioma surgery-mistakes made and lessons learned.
D. Waller (2017)
10.1093/ejcts/ezw215
Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma.
Maurizio Infante (2016)
10.1016/S1470-2045(15)00208-9
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
R. Stahel (2015)
Comorbidity, post operative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma
M Infante (2016)
postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma
M Infante (2016)
10.1378/CHEST.103.4_SUPPLEMENT.382S
Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma.
V. Rusch (1993)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1016/j.jtcvs.2015.09.121
Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy.
H. Batırel (2016)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
National Comprehensive Cancer Network. Malignant pleural mesothelioma: version 1
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/0002-9343(80)90103-5
Multimodality therapy for malignant mesothelioma based on a study of natural history.
K. H. Antman (1980)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1002/(SICI)1097-0142(19980515)82:10+<2057::AID-CNCR14>3.0.CO;2-A
The National Comprehensive Cancer Network
W. Mcgivney (1998)
10.1007/s00595-015-1275-3
Current surgical strategies for malignant pleural mesothelioma
T. Takuwa (2015)
10.1002/1097-0142(197503)35:3<734::AID-CNCR2820350328>3.0.CO;2-N
Indications for pleurectomy in malignant effusion
N. Martini (1975)
Annual report of cancer statistics in Korea in 2014
(2016)
10.1007/s10147-015-0925-1
Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial)
S. Hasegawa (2015)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar